In the panel "The Data Problem in Scaling Artificial Intelligence in Healthcare" at the recent MedCity CONVERGE conference, experts from big pharma and health tech discussed challenges in scaling AI such as data gaps and navigating the potential ethical pitfalls of democratizing data.
In a panel discussion at the MedCity CONVERGE conference exploring the opportunities and challenges posed by the data underpinning AI tools, panelists representing big pharma, health tech and clinical data network shared some of their insights.
At the MedCity CONVERGE conference in Philadelphia Wednesday, Case Western University bioethics professor Insoo Hyun explored the ethical issues raised by use of technologies like CRISPR-Cas9 in humans.
From drug delivery to digital pathology, health tech and medtech startups will make a series of presentations about their technology and milestones they seek to meet at the MedCity CONVERGE conference in Philadelphia at the University City Science Center June 19.
Health tech applications in the realm of cancer treatment will be a major theme of the CONVERGE conference in Philadelphia June 19 in Philadelphia, from improving the patient experience to AI. Register now!
Next month's MedCity CONVERGE conference will include a panel of experts who will talk about the cost and value of new cancer treatments like cell therapies and immunotherapies.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The MedCity CONVERGE conference at the University City Science Center June 19 in Philadelphia will be the scene of a dynamic series of conversations around cancer treatment, precision medicine, value-based care and investment trends. It will spotlight industry experts, presentations from innovative startups and collaborations.
MedCity's conferences this year include a new population health event in New Orleans and a collaboration with HLTH that will see our annual patient engagement conference integrated into HLTH's larger event. The season kicks off April 23 with our annual MedCity INVEST event in Chicago.
MedCity's event calendar is jam-packed with healthcare conferences focused around conversations about precision medicine, innovation in cancer treatment, population health, healthcare startups and investment trends, digital health, and patient engagement.
Not only have a significant number of entrepreneurs had successful exits, but they are going on to start their next healthcare ventures in the Philadelphia area.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
If you missed our conference this week, fear not. We recorded some of the most interesting segments. Check them out.
Me-too drugs and ill-defined AI are less interesting than unmet need and AI with supporting evidence.
Panelists highlight Roche's acquisition of Flatiron Health in February and use of AI/ML in drug development.
At MedCity CONVERGE on July 12, panelists discussed rising oncology costs and posed questions about how the nation is spending its healthcare dollars.
Blood-based cancer tests have market, but more evidence may be needed to verify validity and utility.
